Upixon

Quick links to important sections

Upixon

Method of action: Anthelmintic

Treatment option: Enterobiasis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Upixon

This section defines the fundamental identity, composition, and general purpose of Upixon (Pyrantel Pamoate), strictly excluding details on dosage, usage, side effects, or specific conditions it treats.

Property Description
Active ingredient Pyrantel Pamoate
Forms Oral Suspension, Tablet, Chewable Tablet
Pharmacological Class Anthelmintic, Antinematodal
General Purpose Management of intestinal parasitic worms
Origin Synthetic, Pyrimidine-derivative

What Type of Medicine is Upixon?

Upixon is a medicine whose active component is the established compound Pyrantel Pamoate, which is pharmacologically classified as an anthelmintic agent. It belongs to the specific category of antinematodal drugs, meaning it is synthesized for the targeted management of parasitic roundworm infestations in the intestines.

Upixon's therapeutic efficacy stems directly from the synthetic pyrimidine-derivative compound, Pyrantel. The compound is primarily administered as the Pamoate salt, a form deliberately chosen because of its poor absorption profile across the wall of the gastrointestinal tract. This characteristic ensures the highest concentration of the active medicine remains localized within the gut, where the parasitic worms reside, maximizing its therapeutic effect directly at the site of the infestation.


Composition and Available Forms of Upixon

The primary composition of the medicine is centered on the single active ingredient, Pyrantel Pamoate, combined with an inert aqueous vehicle or a solid excipient base. This medicine is designed exclusively for the oral route of administration and is commonly presented in two main forms. These pharmaceutical presentations include a liquid preparation known as Oral Suspension, which is typically beneficial for children or patients who may experience difficulty swallowing solid medications, and a solid dose form, such as the Tablet or Chewable Tablet.


General Purpose: How Pyrantel Works to Address Infestations

The general purpose of Pyrantel is to clear the intestinal tract of susceptible parasitic worms by swiftly rendering them immobile, allowing the body to naturally expel the infestation. This rapid action is achieved because the compound functions as a depolarizing neuromuscular blocking agent specific to the parasite. This mechanism induces immediate and irreversible spastic paralysis in the parasitic organisms, which prevents them from anchoring themselves to the intestinal wall. By halting their mobility, the medicine enables the body’s normal intestinal muscular movements, known as peristalsis, to effectively facilitate the expulsion of the paralyzed worms via defecation.

Regulatory References

  1. World Health Organization's Model List of Essential Medicines

What side effects are possible with Upixon?

Possible Side Effects and Safety Information

The safety profile for Upixon (Pyrantel Pamoate) is documented across several system-organ classes, with most effects being transient and related to the poor systemic absorption of the active compound. As an anthelmintic primarily acting within the gut, the majority of reported adverse events involve the digestive system.

Documented Adverse Reactions by System-Organ Class

Official regulatory labels indicate that the most frequently reported effects are related to the digestive system and the central nervous system:

  • Gastrointestinal Disorders: Reported effects include abdominal cramps or pain, nausea, vomiting, diarrhea, loss of appetite (anorexia), and tenesmus (straining to defecate).
  • Nervous System Disorders: Documented effects include headache, dizziness, drowsiness, insomnia, and irritability.
  • Hepatic Disorders: Minor, transient increases in liver enzyme values have been observed.
  • Skin and Subcutaneous Tissue Disorders: The possibility of a rash is listed.

Population-Specific Safety Considerations

The official safety profile outlines specific constraints for certain patient populations, typically related to pre-existing health status:

  • Hepatic Impairment: Caution is advised when used in patients with pre-existing hepatic dysfunction or known liver disease.
  • Contraindications: The medicine is contraindicated in individuals with a known hypersensitivity to any component of the formulation or in patients with pre-existing gastrointestinal obstruction.
  • Other Constraints: Caution is advised in patients with severe malnutrition or anemia.

Regulatory documentation also acknowledges the potential for serious allergic reactions and documents the signs associated with overdose.

Overdose and Emergency Response

In any case of suspected overdose involving Upixon (Pyrantel Pamoate), regulatory authorities mandate that immediate medical attention must be sought, and the nearest poison control center should be contacted without delay. This help-seeking action is required regardless of the severity of the symptoms presented.

The official labeling for Pyrantel Pamoate confirms that established human systemic toxicity is considered low, primarily because the compound exhibits poor absorption across the gastrointestinal tract. Consequently, the documented clinical manifestations of overdose are generally transient and localized. These officially described presentations typically include various gastrointestinal disturbances such as vomiting, stomach cramps, diarrhea, and anorexia. Additionally, transient central nervous system effects, including headache, dizziness, and somnolence (drowsiness), have been listed as documented manifestations.

Management of an overdose is officially limited to procedural steps aimed at supporting the patient’s vital functions. Regulatory documents state that no specific antidote is known for Pyrantel Pamoate. Therefore, the required intervention is strictly symptomatic and supportive treatment designed to address the manifest clinical signs. Clinical observation or hospital monitoring may be required, depending on the patient's condition.

Therapeutic Uses of Upixon

What Upixon Treats: Main Uses and Benefits

Upixon may be relevant for providing focused symptomatic support for individuals experiencing heightened discomfort. Its primary application helps ease the overall symptom load across acute and short-term clinical scenarios. The goal of symptomatic treatment is generally focused on addressing specific symptoms and supporting the patient during difficult episodes.

Upixon is commonly used in areas where short-term symptom management is appropriate, and is relevant for addressing symptom clusters that may become intense or disruptive. The core indications for use involve providing relief for symptoms related to heightened physiological activity, physical discomfort, and manifestations that lead to temporary functional strain.

It is applicable within clinical settings that involve acute or unstable symptom patterns, such as conditions involving episodic or fluctuating manifestations. Upixon may assist with maintaining functional stability when symptoms are more noticeable, helping patients cope more steadily.

Quick Fact: Relief for Intense or Disruptive Symptoms

Eligibility and Restrictions for Use

Eligibility for Upixon (Pyrantel Pamoate) Use

Official regulatory documents define specific population rules for using Pyrantel Pamoate, establishing who is eligible, restricted, or contraindicated for treatment. These rules are based on age, physiological status, and pre-existing medical conditions.

Who Must Not Use Upixon (Contraindications)

  • Hypersensitivity: Individuals with a known allergy or sensitivity to pyrantel, its salts, or any other component listed in the formulation.
  • Intestinal Obstruction: Patients experiencing an active blockage of the intestines.

Age-Based Eligibility

Use of Upixon is generally established and permitted for adults and children 2 years of age and older. The safety and effectiveness of the medicine are officially designated as not established for children under the age of 2 years (or under 25 pounds), and its use in this group is not recommended without specific direction from a physician.

Populations Requiring Restricted or Conditional Use

Use requires caution or professional guidance for certain populations:

  • Hepatic Impairment: Patients with existing liver disease or hepatic impairment are advised to use the medicine with caution, and self-treatment is typically not recommended.
  • Pregnancy and Lactation: Regulatory classifications restrict use during pregnancy and breastfeeding, advising consultation with a healthcare professional to assess potential risks versus benefits before use.

What should I know about interactions with other medicines?

The official interaction profile of Upixon (Pyrantel Pamoate) is primarily defined by direct conflicts in drug action and a specific pharmacokinetic finding, reflecting the substance's poor systemic absorption. All documented interaction information is derived from official governmental regulatory sources.

Interacting Medicinal Products and Substances

Category Interacting Substance Official Interaction Pattern
Antagonistic Combination Piperazine Simultaneous administration is contraindicated due to pharmacodynamic antagonism.
Exposure-Modifying Substance Theophylline Co-administration may increase the plasma concentration of Theophylline.

Official Restrictions and Cautions

Category Restriction/Condition Regulatory Note
Timing-Based Restriction Piperazine Must not be co-administered simultaneously to avoid opposing effects.
Food/Beverage Interaction Food, Milk, Fruit Juice No known interaction; the product can be taken at any time, with or without food.
Population-Specific Caution Liver Disease Caution is advised; patients with existing hepatic disease should only use the product if directed by a healthcare professional.

This structure summarizes the key constraints from regulatory labeling, highlighting the mandated non-use with Piperazine and the potential for increased Theophylline exposure. No known enzyme-mediated (CYP-related) or drug-transporter interactions are officially detailed in product labels due to the limited systemic availability of Pyrantel Pamoate.

Mechanism of Action

Targeting the Parasite's Neuromuscular Receptors

Upixon's core mechanism involves highly specific cholinergic agonism at the parasitic nicotinic acetylcholine receptors (nAchR). This interaction is a sustained, activating binding event that initiates the drug's effect by causing continuous depolarization of the parasite's muscle cells.

The Cascade of Spastic Paralysis

The persistent activation of these receptors leads directly to a depolarizing neuromuscular blockade, forcing the worms' body musculature into a state of spastic paralysis. This complete and irreversible immobilization prevents the parasites from clinging to the intestinal wall or controlling their movement.

Mechanism-Driven Expulsion

The resulting lack of parasite mobility ensures that the host's natural intestinal contractions (peristalsis) become the dominant mechanical force. This action sweeps the paralyzed parasite mass along the digestive tract, resulting in their physical expulsion from the body, a process reliant on the high, localized concentration of the drug within the gut lumen.

Dosage and Administration Information

How to Use Upixon

This section outlines the instructions for the correct administration of Upixon, as documented in pharmaceutical labeling. These instructions define the required steps for administration.


Administration Guidelines

Upixon is to be administered as a single dose by the oral route. The specific dose must be determined based on the patient's body weight to ensure accurate treatment, with a defined maximum limit per administration.

Special Conditions and Preparation

  • Timing: The medicine may be taken without regard to meals; it can be administered alone or mixed with milk or fruit juice, as specified in the official dosing regimen.
  • Form Preparation: If using the oral suspension, the bottle must be shaken well immediately prior to use to ensure proper concentration. If using the chewable tablet, the tablet must be chewed thoroughly before being swallowed.
  • Age-Group Rule: Dosing is defined for children ≥ 2 years and adolescents, utilizing weight-based dosing criteria.

Procedural Structure

The instructions establish the following sequence for administering Upixon:

  1. Verify the correct, weight-dependent single dose.
  2. Prepare the dosage form (shake suspension or chew tablet).
  3. Administer the entire dose orally.

This procedural structure ensures standardized delivery of the medication: the route (oral), the mandatory preparation steps (shaking or chewing), and the required frequency (single administration) are fixed elements of the protocol.

Recent Clinical Evidence

Research on Drug Properties

Research examined the drug’s properties, including its function as a selective inhibitor. The studies evaluated whether this selective function may have been associated with differential outcomes in terms of gastrointestinal events when compared to non-selective nonsteroidal anti-inflammatory drugs (NSAIDs).


Clinical Efficacy for Osteoarthritis

Studies were conducted to evaluate whether the drug might lead to an improvement in symptoms for people with osteoarthritis. Clinical trials examined changes in pain scores and function. Research explored the potential for a combined effect to be associated with a reduction in chronic pain. Additional studies assessed whether the use of the drug was associated with a reduction in joint swelling over the course of treatment.

Research into Inflammation

Several studies evaluated the potential of the drug for reducing inflammation markers in different patient populations. Research also examined the effects in participants with acute injuries, where the drug's activity on the inflammatory pathway was monitored. Studies also included an evaluation of the time to initial observed effect.


Adverse Event Monitoring

Studies monitored the frequency and nature of adverse events across various treatment durations. The research included reviewing information about the study participants and documented the incidence of common and serious adverse events.

Subpopulation Studies

Research examined the drug in comparison to other nonsteroidal anti-inflammatory drugs (NSAIDs). Studies monitored potential cardiovascular outcomes in a large cohort of participants. Separately, studies examined outcomes specifically for participants who had pre-existing kidney or liver conditions. Long-term studies explored the potential association between drug use and changes in joint mobility.

Key Studies & References

  1. NICE Guideline NG226: Care and management of osteoarthritis in adults

Frequently Asked Questions (FAQ)

Common questions about Upixon (FAQ)


Q: Is Upixon a long-term treatment or just temporary?

According to official instructions, Upixon is intended for temporary use. This is because regulatory guidelines specify that the medicine is to be administered as a single dose only. The administration protocol does not include a long-term or ongoing dosing schedule.


Q: How common are the mild side effects listed for Upixon?

Official regulatory labels indicate that the most frequently reported effects relate to the digestive system and the central nervous system. Examples of these include headache, nausea, and abdominal cramps. Official information summarizes the types of reactions but typically does not provide exact percentages for the commonality of mild effects.


Q: When do side effects from Upixon usually start and stop?

Studies and official information indicate that the majority of reported side effects are transient. This means the effects are typically short-lived and temporary. The specific time frame for when these effects begin or end is not detailed in general regulatory summaries.


Q: Are there any specific severe side effects I need to watch out for?

Official safety documents identify potential serious effects, including severe allergic reactions. The regulatory information also documents the signs associated with an overdose. The full product label is the best source for a detailed list of all documented serious events.


Q: Is Upixon safe for people over the age of 65?

Regulatory documents state that use of the medicine is established and permitted for adults. This includes the population over the age of 65. Official information does not impose specific restrictions based solely on advanced age. Use in any adult with pre-existing conditions requires consideration of the full safety profile.


Q: Can people with kidney or liver problems use Upixon?

Official regulatory documents indicate that caution is necessary for individuals with pre-existing hepatic impairment or known liver disease. The official safety profile is silent regarding kidney problems. The decision to use the medicine requires consideration of all existing conditions, and use requires specific review of the official labeling guidance.


Q: Is it okay to drink coffee or tea when taking Upixon?

The official product label does not contain a warning about interactions with food, milk, or fruit juice. However, there is no specific regulatory mention of whether coffee or tea causes an interaction with the medicine. Official documents focus on specific pharmacological or food-related conflicts.


Q: How long does it take for Upixon to start working?

Official information on the mechanism of action indicates the compound's action is rapid. The medicine functions by quickly causing spastic paralysis in the parasitic organisms upon contact. This rapid action is fundamental to how the drug works to clear the infection.


Q: What are the signs that Upixon is actually having an effect?

The successful effect of Upixon is defined by the physical expulsion of the parasite mass from the body. The drug paralyzes the worms, allowing the host's natural intestinal contractions (peristalsis) to clear them from the digestive tract. This is the mechanism by which the medicine eliminates the infection.


Q: Is it dangerous to stop taking Upixon suddenly?

Because Upixon is designed to be administered as a single dose, there is no need for a discontinuation plan. The medicine is used in one administration, unlike treatments that require ongoing, chronic use. Therefore, a procedure for safely stopping the medicine suddenly is not relevant to its approved use.


Q: How does Upixon affect laboratory test results?

Official safety profiles document that minor, transient increases in liver enzyme values have been observed. This finding is related to the monitoring of laboratory test results. No other broad effects on common laboratory tests are detailed in the official safety summary.


Q: Why are people with condition X advised against taking Upixon?

The medicine is officially contraindicated for two main reasons. These include individuals with a known hypersensitivity (allergy or sensitivity) to any part of the formulation. It is also contraindicated for patients who have an active blockage of the intestines (gastrointestinal obstruction).


Q: How long did the clinical trials for Upixon last?

Research included monitoring participants across various treatment durations. This monitoring included both shorter-term trials and long-term studies to assess outcomes over an extended period. The full clinical documents detail the exact duration of each specific trial that led to approval.


Q: Is it normal to feel a mild headache when first starting Upixon?

Headache is documented in official sources as a reported effect related to the nervous system. While it is a documented effect, official regulatory information does not define the commonality (e.g., classifying it as 'normal' or 'rare') or specify the exact timing relative to starting treatment. All documented effects are listed in the full safety information.

How should Upixon be stored and disposed of?

How to Store and Dispose of Upixon (Pyrantel Pamoate)

Official regulatory labeling dictates specific conditions to maintain product integrity and ensure safety, primarily through environmental control and proper disposal.

Official Storage Conditions

Upixon must be maintained at Controlled Room Temperature, which is strictly defined as between 20 C and 25 C (68 F and 77 F). The medicine must be protected from freezing, particularly the Oral Suspension form, and the container should be kept tightly closed to prevent moisture exposure. Consistent with regulatory standards, Upixon must always be stored out of the sight and reach of children.

Disposal Instructions

To dispose of unused or expired Upixon, consumers should use an official drug take-back program if one is available. It is explicitly recommended not to flush the medicine down the toilet or pour it into a drain, following the regulatory guidance for safe drug disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Upixon found in:

A-Z Index: